Welcome to our dedicated page for Neuropace SEC filings (Ticker: NPCE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NeuroPace, Inc. SEC filings document the company's medical-device business, Nasdaq-listed common stock and public-company reporting obligations for the RNS System epilepsy therapy. Form 8-K reports cover operating results, financial condition, corporate updates, material agreements, clinical or regulatory disclosures, and executive or compensation-related events.
Proxy filings describe NeuroPace governance matters, including annual meeting proposals, director elections, auditor ratification and stockholder voting mechanics. The filing record also provides formal disclosure on capital structure, officer transitions, separation or consulting arrangements, and risk areas associated with commercialization, clinical evidence and regulatory oversight of neurostimulation devices.
Joel Becker, Chief Executive Officer and director of NeuroPace Inc. (NPCE), reported a non-discretionary share disposal on 08/27/2025. The filing shows 1,126 shares were withheld by the issuer at an effective price of $8.88 to satisfy tax withholding tied to the vesting of a restricted stock unit award. After this withholding, Becker beneficially owns 104,212 shares, held directly. The form was signed by an attorney-in-fact on 08/28/2025 and records the transaction as a routine tax-withholding disposition related to equity compensation.
NeuroPace insider reported a small share disposition tied to tax withholding on vested restricted stock units. The Form 4 shows Chief Medical Officer Martha Morrell had 357 shares withheld on 08/27/2025 at an effective price of $8.88 per share to satisfy tax obligations related to RSU vesting. After the withholding, Ms. Morrell beneficially owns 84,817 shares directly.
This is a routine, non-open-market disposition for tax purposes rather than an active sale; the filing was signed by an attorney-in-fact on 08/28/2025.
NeuroPace Inc. (NPCE) reporting person Martha Morrell, Chief Medical Officer, filed a Form 4 disclosing transactions on 08/20/2025. The filing shows 3,052 shares of Common Stock were disposed at a price of $8.66 each; the form explains these shares were withheld by the issuer to satisfy tax withholding on the vesting of a restricted stock unit award. After the transaction, the reporting person beneficially owned 85,174 shares (the filing reports this as a disposition entry). The filing also notes an acquisition of 2,283 shares pursuant to the NeuroPace, Inc. 2021 Employee Stock Purchase Plan. The Form 4 is signed by an attorney-in-fact on behalf of the reporting person and lists Mountain View, CA as the reporting person’s address.
OrbiMed Advisors LLC and its affiliate OrbiMed Capital GP VI LLC report shared beneficial ownership of 2,614,184 shares of NeuroPace Inc common stock, representing 8.0% of the outstanding class. The filing states the reported shares are held on behalf of other persons and that OrbiMed Advisors exercises investment and voting power through a management committee of three named members, each disclaiming beneficial ownership. The statement affirms the holdings were not acquired to change or influence control of the issuer. No additional transactions, dispositions, or other contingencies are disclosed in the filing.
NeuroPace reported sequentially stronger commercial results with improving margins but continued net losses and new financing activity that reshaped its balance sheet. Revenue for the quarter was $23.5 million, up 22% from the year-ago quarter, producing gross profit of $18.1 million and a gross margin of 77.1% versus 73.4% a year earlier. The company recorded a net loss of $8.7 million ($0.26 per share) for the quarter and a six-month net loss of $15.2 million.
NeuroPace ended June 30, 2025 with $62.1 million of cash, cash equivalents and short-term investments. In February 2025 it completed a follow-on offering that generated $69.7 million net proceeds and used $49.5 million to repurchase shares from a significant stockholder. In June 2025 NeuroPace replaced its prior CRG term loan with a $60.0 million MidCap term loan and had $58.6 million of long-term debt, net. The company remains in compliance with its MidCap covenants, reporting trailing 12-month RNS System revenue of $71.6 million and stating its cash resources are expected to fund operations for at least 12 months.
NeuroPace, Inc. reported that it issued a press release announcing its financial results for the fiscal quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 to this current report and is incorporated by reference into the filing. The company explicitly states that the information in Item 2.02, including the exhibit, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act nor incorporated by reference in filings under the Securities Act except by specific reference. No financial figures or earnings metrics are included in the text of this report.
Amendment No. 5 to Schedule 13G discloses that investment vehicles affiliated with Soleus Capital and managing member Guy Levy collectively own 2,303,828 shares of NeuroPace, Inc. (NPCE), equal to 7.0 % of the 32,798,505 shares outstanding on 05-09-25.
Key holders: (1) Soleus Capital Master Fund, L.P. – 1,993,507 shares (6.1 %); (2) Soleus Private Equity Fund I, L.P. – 310,321 shares (0.9 %). All entities report shared voting and dispositive power and zero sole voting/dispositive power. The filing, made 08-05-25 for an event on 06-30-25, is submitted under Rule 13d-1(c), indicating a passive investment with no intent to influence control.
The updated 7 % stake places Soleus Capital among NPCE’s largest shareholders, giving it material but not controlling influence; no financial results or transaction terms accompany the disclosure.
NeuroPace CFO Patrick F. Williams received significant equity compensation on June 20, 2025, consisting of two main components:
Restricted Stock Units (RSUs):
- 51,850 RSUs granted at $0 cost
- Vesting schedule: 25% vests on June 20, 2026, remaining vests quarterly over 3 years
Stock Options:
- 87,950 options granted with strike price of $10.41
- 10-year term, expiring June 19, 2035
- Same vesting schedule as RSUs: 25% after one year, then quarterly over 3 years
This compensation package demonstrates NeuroPace's strategy to align executive interests with long-term shareholder value through equity incentives with extended vesting periods.
NeuroPace, Inc. (NPCE) – Form 3 Initial Statement of Beneficial Ownership
Chief Financial Officer Patrick F. Williams filed an initial Form 3 for an event dated 06/20/2025. The document confirms that he currently holds no beneficial ownership—neither common stock nor derivative securities—in NeuroPace. The filing was signed by attorney-in-fact Leah Akin on 06/24/2025.
Form 3 is required when an individual becomes a Section 16 insider (director, officer, or >10 % shareholder). This submission fulfills that requirement and sets Williams’s baseline ownership level for future insider transaction reporting.
On 24 June 2025, NeuroPace (NPCE) filed a Form 4 for director Dr. Uri Geiger detailing a series of stock grants received as part of the company’s non-employee director compensation policy, issued in lieu of cash retainers.
- Latest grant: 1,140 shares on 21 June 2025 at $10.41.
- Cumulative direct holdings: 12,036 common shares after the reported transactions.
- Grant history: Eight quarterly issuances from 30 June 2023 through 21 June 2025, priced between $4.49 and $13.20, all coded “A” (acquisition).
- Indirect holdings: 4,432,948 shares held through Accelmed Partners II LP, over which Dr. Geiger exercises sole voting and dispositive control.
No shares were sold, and there are no derivative security movements disclosed. The filing is administrative, reflecting routine equity compensation rather than a strategic insider transaction.